Peter Park, Ph.D


Diana Mandelker, M.D., Ph.D

Description: This presentation will continue the discussion of the potential use of PARP inhibitors with an emphasis on advances in laboratory practices for identification of homologous recombination deficiency in sequencing data. This session will examine the challenges inherent to biomarker testing for PARPi response, including for patients whose tumors lack mutations in BRCA1/2.



 Duration: 1 hr

Level of Instruction: Basic

AMA PRA Category 1 Credit(s) &trade


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

CMLE Credit: The ASCP designates this activity for a maximum of 1.0 Continuing Medical Laboratory Education (CMLE) credit hour. CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

SAM Credit: This activity is approved by the American Board of Pathology for up to 1.00 SAM credit. Physicians should claim only credit commensurate with the extent of their participation in the activity. Learners must pass the post-test with a score of 80% or higher and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available.  If you are seeking continuing education credit for an accrediting board other than the ABP, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. 

“Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors” is an up-to-date and useful three-part webcast series that will cover: 1. The mechanism of action of PARP inhibitors and the science of Homologous Recombination Deficiency (HRD) testing, 2. Laboratory considerations (from sample acquisition to result reporting) for HRD testing, and 3. Clinical considerations for testing and treatment and the need for genetic counseling.

This program has been supported through educational grants from AstraZeneca & Merck

Course Objectives
  • Define patterns of genomic alterations in tumors with homologous recombination deficiency.
  • Employ techniques for detection of homologous recombination deficiency in sequencing data.
  • Describe the clinical correlations of homologous recombination deficiency including PARPi outcomes.
Course Information
Date Presented:
August 29, 2019 1:00 PM Eastern
1 hour
AMP Regular Member Price:
AMP Technologist Member Price:
AMP Associate Member Price:
Non-member Price:
Registration for this event is closed
LIVE WEBINAR: Identifying Mutational Signatures of Homologous Recombination Deficiency to Predict PARPi Response
Individual topic purchase: Selected